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Abstract It is well established that nitric oxide is an effective vasodilative, antibacterial and 
tumoricidal agent, however its targeted delivery in a controllable manner is challenging but 
necessary for successful therapeutic applications. In recent years a few new methods have been 
developed, based on the formation of N-diazeniumdiolates, S-nitrosothiols and metal –NO 
coordination bonds in material structures. The typical delivery materials include nanoporous 
materials (such as zeolites and metal organic frameworks), silicate particles and polymers 
containing amine and thiol functional groups. These materials are of promising potential for 
delivering controllable doses of bioactive NO gas to meet the unmet therapeutic needs in the future. 
This review summarises these delivery materials and relevant biological assessments.  Further 
improvement of current methods and new design of NO donors are still required in order to address 
the issues on NO storage and its release profile in matching with the clinical requirements.        
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1. Introduction  
Nitric oxide (NO), as a cellular signalling molecule, plays pivotal roles in many physiological 
and pathological processes in the body, either by permeating into cells or binding to proteins to be 
carried off to all parts of the body. It is highly effective in its vasodilative, antibacterial, and 
tumoricidal functions, and is of growing interest for potential therapeutic applications. In the body, 
endogenous NO is produced either through Nitric Oxide Synthase (NOS) catalysing the 
metabolism of L-arginine or by non-enzymatic nitrite reduction. Accordingly, a series of NO 
donors have been developed containing L-Arginine, L-citrulline, glyceryl trinitrate, amyl nitrite, 
sodium nitroprusside, isosorbide mononitrate, S-nitrosothiols, the N-diazeniumdiolates and 
mesoionic oxatriazoles [1-3]. Alternatively, pure NO gas can also be directly delivered into the 
body from external sources. Currently, direct delivery of NO by inhalation has been approved for 
use in clinical settings for the treatment of persistent pulmonary hypertension and hypoxic 
respiratory failure in newborns [4]. Other important functions as an antimicrobial agent and a 
promoter of wound healing require further developments to progress into clinical settings. Due to 
nitric oxide gas nature and short half-life, it is a challenge for establishing suitable methods for 
delivering NO gas in a controllable manner. The design of new NO donors is thus required to 
address the issues existing in current donors e.g. poor storage capacity, donor stability, controllable 
NO release and potential toxicity of NO donors.   
In recent years, the hybrid NO donors have been developed by means of (1) NO covalently 
bonded to substrates, i.e. S-nitrosothiols, N-diazeniumdiolates, and (2) NO chemisorption on metal 
active sites in materials by metal-NO complexes. The NO chemisorption stands up as a new 
method for bioactive NO delivery, which recently is of particular interests for topical therapeutic 
applications due to the direct release of pure NO gas thus avoiding potential toxic by-products [5]. 
The typical examples are the functionalised solids in the forms of polymers, silicate particles, metal 
organic frameworks (MOFs), zeolites and composites. They are advantageous over the small 
molecular donors in controlling NO storage and release as well as in reducing the undesirable 
species leaching [6], showing their potential for wound healing over the classic NO donors [7]. 
Since so far the research is still very limited on this new class of NO donors, this paper will focus 
on reporting the progress in the research of this type of materials for nitric oxide storage and 
release. While the controlled release of NO is a primary target for all of these materials, this review 
will not focus on the quantitative measurement or the various methods used to determine NO 
release, as this has been covered in detail in other recent reviews [8].  
For functionalised porous solids delivering bioactive nitric oxide, three different strategies can 
be adopted, that is, (a) coordination of unsaturated metal sites present in the materials to form 
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metal-NO complexes, for example, in metal ion exchanged zeolites (LTA and FAU) and porous 
metal-organic frameworks (MOFs); (b) the amine groups in the materials to react with nitric oxide 
to form N-diazeniumdiolate (R2N-NONOates) structures; and (c) nitroso group bonded to amine 
or thiol moieties i.e. R1N(–R2)–N=O or RS-N=O in materials. These strategies can be combined 
in the design of materials suitable for controlling NO release. The storage capacity of nitric oxide 
significantly depends on the chemical composition and pore structure of materials that determine 
the NO-releasing kinetics. The ideal materials are not only capable of storing a high quantity of 
nitric oxide gas but also releasing the gas in a controllable manner to suit therapeutic requirements.  
2. Functionalised nanoporous materials for NO storage and release          
2.1 Zeolites as NO donors  
Zeolites are porous aluminosilicate minerals, well known as effective catalysts for the 
reduction of nitric oxide pollutant at high temperature (~ 400 oC). This catalytic process is mainly 
composed of surface adsorption and surface reaction, different nitrogen oxide species are usually 
formed over the active metals (Cu, Fe, Co, Ag, Ni, Ga, Ce, Mn) catalyst surfaces with the formation 
of non-toxic nitrogen. For medical use such as wound healing, it requires zeolites to be able to 
deliver pure nitric oxide to specific locations of interest at relatively low releasing temperature 
without coexistence of different nitrogen oxide species. It also requires that in topical therapies the 
nitric oxide is discharged in a biologically friendly manner, i.e. triggered by moisture, light, and 
body temperature. Obviously, triggering NO release by skin moisture is the most convenient 
method. Previous studies have shown to some extent these requirements can be satisfied using 
metal-exchanged zeolites in which NO gas is stored at ambient temperature without such surface 
reactions at high temperature.  
The concept of using zeolites as the NO donor is of great significance for practical applications 
of nitric oxide in the biomedical fields. The pioneering research has been led by the Morris group 
[9-11]. The typical zeolites, Linde type A (LTA) and Faujasite (FAU), were initially examined for 
storing NO. In order to store high capacity of NO, it is a prerequisite to exchange zeolites with 
metals, followed by a dehydration at ~573 K prior to NO loading. This features two processes:  
firstly, the sodium cations that balance framework negative charges and also block pores are 
removed through the exchange of divalent metal cations (Cu2+, Co2+, Ni2+, Mn2+ and Zn2+ etc) with 
smaller ion radii. The closed pores are thus opened. This allows NO gas more freely diffusing 
along the pores to access the metal sites where NO is adsorbed. This is particularly crucial for LTA 
zeolites because it consists of smaller size porous channels (~4.1 Å) than the zeolite FAU (~7.4 
Å) [12]; secondly, the introduction of the transient metals as active adsorption sites affects the 
electric field gradient of cavities and the acidic or basic character of the framework [13], and thus 
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regulate zeolite affinity to adsorb nitric oxide and the NO-releasing rate.  
Nitric oxide is commonly used as a probe molecule for the characterisation of Lewis acidic 
sites in zeolites [14]. It can coordinate with metals by two different modes - either nitrogen or 
oxygen binding with metal, exhibiting different geometries. In an ion exchanged zeolite, it prefers 
to form metal-NO complexes rather than metal–ON in a bent geometry. Fig. 1 (a) showed NO 
coordinated with extra-framework cobalt cations residing in pore channels of zeolite LTA. The 
angle Co-N-O in LTA is 141o, whereas the Mn-N-O in zeolite FAU is 79o. The difference of NO 
complex geometry relies on the varying coordination environments, such as the charge of NO 
molecule, the coordination number, the coordination geometry and the nature of the highest 
occupied molecular orbital [15]. The electron transfer between NO and the unsaturated metal 
cations equates to strong bonding of NO to zeolites, to defend against the pulling force imposed 
by means of reducing NO pressure. Due to the exchange of electrons and the resultant strong bonds 
formed, adsorption and desorption of nitric oxide on metal exchanged zeolites are irreversible (Fig. 
1 (b)).  
Experiments showed that at 1.0 bar loading pressure, the irreversible amount of NO adsorbed 
in LTA and FAU were in a ranges of ~1.2 – 2.7 mmol g-1 [11,16,17]. The NO-releasing was 
triggered by exposing these zeolites to humidified atmosphere and lasted at 50 ppb level in a time 
scale of more than 2 hours. The NO delivered by zeolites is high potency in the inhibition of 
platelet aggregation [10]. The hysteretic nature of the adsorption/desorption isotherm can be 
regarded as an indicator of material suitability for effectively storing and delivering NO. Similarly, 
the Al- and Ga-doped porous titanosilicate ETS-10 ((Na,K)2TiSi5O13) materials exhibit the storage 
capacity in the same range of ~1.1- 1.7 mmol g-1. Importantly, these materials have very low 
toxicity (cell viability above 87%, after 72 h) at high concentration (0.45 mg cm-3) [18a]. 
Cytotoxicity of NO delivery materials is crucial when the materials are administrated inside the 
body or applied for topical therapies, which must have to be assessed before medical use.    
To avoid the risk of cytotoxicity, it may be good to develop zeolite donors without the toxic 
metals exchanged. Zhu et al studied the γ-aminopropyltriethoxysilane (APTES) post modification 
of HZSM-5 zeolite, mesoporous zeolite, and MCM-41 mesoporous materials for NO storage and 
release [18b]. NO was preloaded in these materials, followed by releasing in mimic gastric juice 
solutions with pH 1.2. Obviously, incorporation of aminopropyl enhanced the NO loading in these 
materials. In the case of aminopropyl modified MCM-41, NO loading increases from 0.77 to 27.43 
μmol g-1. Although the quantity of NO stored or released is much less than that of metal exchanged 
zeolites, they do not contain toxic metals. These porous materials exhibit multifunction feature. 
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They can release NO, and simultaneously remove carcinogenic nitrosamines e.g. N –
nitrosopyrrolidine and N-nitrosonornicotine from the gastric juice solution.     
2.2 Nitric oxide releasing kinetics of zeolite biomaterials  
Nitric oxide releasing kinetics can be used for the material assessment or screening. The NO 
release from zeolites triggered by water follows the pseudo first - order kinetics as described by 
the following equation;  
...)1()1( 21 21 
 tktk
t eMeMM , 
where the k1 and k2 are the releasing rate constants for sites I and II; Mt, the releasing amount at 
time t; M1 and M2, the releasing amounts from sites I and II. This model has been based on the 
hypothesis that the NO adsorption occurs in different active sites without any interactions. In most 
cases, the two - term equation is used for fitting experimental data with the deviation of less than 
1.0% and regression coefficient of R2 > 0.990, which implies that two distinct active sites exist in 
the zeolite and thus the NO release can be distinguished by the different kinetic constants k. For 
example, the NO released from Mn-LTA (in Fig. 2) has smaller k1 than k2, indicating that the site 
I is in favour of discharging NO more slowly than the site II. Accordingly, when a long duration 
of NO release is required, more NO adsorbed on the sites I would be desirable. Otherwise, for a 
quick NO release, adsorption on sites II would be expected. Apparently, this classification is 
arbitrary because the performance of NO release from such zeolites depends on a variety of factors 
such as water diffusion, NO surface displacing reaction, metal location and distribution in zeolites, 
metal properties, framework chemical composition and structures. Homogeneous NO release has 
been observed in the manganese and cobalt exchanged FAU zeolites (Mn-FAU and Co-FAU). In 
this case, the two-term kinetics degenerates into one item, implying that the active sites are uniform 
and NO releases only from one uniform site without the second site (M2 = 0).  
The stretched exponential model Mt/Me = 1-exp(-(kt)
β
) was also investigated, where Mt is the 
adsorbed amount at time t; Me, the equilibrium uptake; k, the rate constant;  β, exponent. This 
model fits the NO-releasing profile from microporous titanosilicates ETS-4 and ETS-10, 
containing the unsaturated pentacoordinate Ti4+ and hexacoordinate Ti4+, respectively [18c]. 
Although this model has a good fit to the experimental data, the variation of exponent β made it 
difficult to assess the performance of materials.  
To satisfy the specific medical requirements, adjusting the NO-releasing kinetics can be 
possibly achieved by changing the framework composition (metal cations exchanged) and 
modifying pore structure and surface properties. In addition, the zeolites can be formulated into 
polymer composites with tunable hydrophilic and hydrophobic properties. For instance, zeolite A 
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was embedded within porous polylactic acid fibres of a nonwoven mat generated by 
electrospinning. As a result, the NO release was effectively regulated through the molecule 
diffusion restriction [19]. NO-releasing kinetic study will provide an important tool for the 
evaluation of material performance.  
2.3 Nanoporous MOFs as NO donors  
As a new type of porous materials, nanoporous metal-organic frameworks (MOFs) have 
demonstrated the advantages in the fields of gas adsorption and drug delivery over other materials. 
This is ascribed to MOFs’ diverse structures, constructed through the assembly of organic ligands 
and metals, with tunable pore structures, chemical composition and functionalities [20-23]. These 
properties make nanoporous MOFs becoming a promising candidate for the NO delivery.  
2.3.1 Open metal site role in MOFs 
Nitric oxide has a strong affinity to interact with coordinatively unsaturated metals (also called 
open metal sites (OMS) in MOFs) in materials even at elevated temperature; similarly, this should 
be the same in the case of MOFs containing the OMSs. The proof-of-concept of NO interaction 
with the OMSs of MOFs has been approved through the examination of a copper 
benzenetricarboxylate MOF (HKUST-1: Cu3(BTC)2(H2O)3; BTC:1,3,5-benzenetricarboxylate) as 
the NO storage material [24]. HKUST-1 contains Cu2 units coordinated by four carboxylate 
groups. There are two cages present in HKUST-1: one smaller pocket cage and one bigger cage 
with coordinated water pointing to it. The smaller pocket cage inside an octahedral unit (called 
secondary building unit SBU) is built of Cu2 dimers at its six vertices coordinated by four BTC 
ions. The bigger cage is built by eight such SBUs; ~ 1.0 nm size channel crosses through these 
cages [25]. The water or other solvents can be removed from the cages and copper sites after a 
proper activation approach is taken (such as activation at ~ 120 oC under vacuum). The activation 
allows NO to be chemically adsorbed on the OMS and physically adsorbed in cages. The capacity 
of NO adsorbed in MOFs reaches to ~ 5.0 mmol g-1 of the dehydrated sample, ~ 5 - 7 times of that 
of zeolites and other materials [10,26]. Biological studies showed that the NO released is potent 
for the inhibition of platelet aggregation. 
The infrared (IR) spectroscopy investigation elucidates the mechanism of NO adsorption in 
MOFs (HKUST-1) related with the OMS. The formation of a Cu(II)-NO adducts reveals the 
crucial role of OMS for storing high capacity of NO [24]. In a contrast, the MOFs without OMS 
adsorb much less NO, although they are porous. A hysteresis was observed between NO adsorption 
and desorption, attributed to the stronger coordination bonds of NO with copper OMS, which is 
similar to that of the metal-exchanged zeolites. From these results, it can be seen that the MOFs 
suitable for high NO storage should contain a high fraction of OMS in frameworks.  
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The high NO storage of up to ~7.0 mmol g-1 has been observed over the nanoporous MOFs 
(CPO-27) [M2(C8H2O6)(H2O)2]·8H2O (M: Co and Ni). This type of MOFs adsorbs NO ~7 times 
than the zeolites [27a]. Taking the metal fraction of ~ 7.0 – 8.0 mmol g-1 in MOF into account, it 
looks likely that all the metal sites (Co or Ni) are accessible to the NO at a low NO equilibrium 
pressure of < 1.0 bar. The NO adsorption isotherm has a Langmuir adsorption characteristic. The 
stored NO can be fully released using a moisture triggering approach. Such unprecedented result 
is ascribed to the unique one-dimensional honeycomb pore structure and the framework surface 
chemistry. The cobalt CPO-27 stores slightly less NO, and releases NO more slowly than the 
analogous Ni-MOF. Obviously, in this case, the metal property determines NO-releasing kinetics. 
This type of MOFs has a long time of NO release (> 14 hrs), which is an advantage when it is used 
for topical therapy for chronic wound healing.  
The adsorption capacity is one of the key parameters to determine material efficacy in gas 
adsorption. A big reservoir of gas stored in the materials will provide more opportunities for 
tailoring the NO-releasing flux and rate in order to meet medical needs. At low adsorption 
temperatures (e.g. 196 K, dry ice), the NO adsorption includes a portion of NO physisorbed in the 
pores after the OMSs become saturated, which can be simply discharged by reducing pressure. 
The whole scenario of adsorption-storage-delivery was described by Morris et al (in Fig. 4) 
[27a]. Every step in the cycle determines whether or not NO is delivered effectively. This cycle is 
derived based on a judicious examination of crystallographic structure variation with NO loading 
and release. An effective material must be able to provide a considerable number of adsorption 
centres. After proper activation, the metal sites previously blocked by the coordination of small 
molecules (water or other solvents) will be opened to allow NO molecules to attack. Consequently, 
a maximum adsorption is allowed to be achieved (that is, the metal sites are saturated by NO 
molecules). No catalytic conversion of the NO bound to metals occurs; this requires a material 
catalytically inactive at room or body temperature, thereby a considerable amount of pure NO is 
delivered. There are a few approaches to trigger NO release, including UV and microwave 
irradiation, thermal treatment and water displacement, among which water discharging NO is the 
simplest and most biologically-friendly method.  
2.3.2 Other effects 
In addition to the fraction of open metal sites in MOFs, the nature of the connection between 
metals and organic ligands, the pore and cage properties (size, shape and dimensionality), and 
framework flexibility and functionality also impact NO adsorption and release characteristics. If 
MOF particle size is an issue for medical uses, now small size MOF particles such as HKUST-1 
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can be conveniently obtained [27b]. Pinto et al studied the Co- and Ni-MOFs built from vitamin 
B3 (nicotinic acid) for NO storage and release [27c]. They carried out the density functional theory 
analysis of NO interaction with MOF frameworks. The result showed that besides the metal site 
coordinating with NO the neighbour uncoordinated carboxylic oxygen atom make a bond with the 
N atom of the NO (d = 2.11 Å). Such interaction between NO and functionality of organic ligand 
stabilises the NO molecule bonded to the metal centre and hence influences the NO- releasing.   
In the case of MOF Cu-SIP (Cu2(OH)(C8H3O7S)(H2O)), it contains a copper cluster Cu4(OH)2 
coordinated by four -COO groups from ligand 5-sulfoisophthalate in a butterfly-like structure with 
the head and tail coppers coordinated with water only (Fig. 3(a)) [28]. Accompanying with the 
hydration-dehydration-rehydration (loss of the water at 370 < T < 405K) process, a reversible 
single-crystal to single-crystal transformation occurs. This has been demonstrated by in situ 
diffractions at a variable temperature (in Fig.  3 (a) and (b)) [29]. Such a chemical transformation 
occurs with respect to the rearrangement of the weaker sulfonate-metal bonds. Its structural 
flexibility in response to NO induction led to a gating adsorption effect; when NO pressure is 
beyond the threshold, MOF framework is opened and starts to adsorb NO (in Fig. 3 (c)). This 
phenomenon was also observed by Kitagawa et al on the porous coordination polymer built from 
zinc and tetracyanoquinodimethane (TCNQ), involving the charge-transfer interaction between 
TCNQ and NO guests accommodated in pores [30]. This framework property attributes some 
MOFs with exceptional high adsorption selectivity to NO. 
2.3.3 N-Diazeniumdiolate functionalised MOFs 
Although the coordinatively unsaturated metals in MOFs (or zeolites) play a key role in 
enhancing NO storage and regulating NO release rate, the incorporation of a diversity of functional 
groups (–Br, –NH2 and –OC3H7 etc) in the MOFs, that are either inherited from organic ligands or 
a result of post-synthetic modification, provides an increased chance of achieving the objective 
[31-33]. Over the last few decades, N-diazeniumdiolate compounds have been widely investigated 
due to their capability of releasing NO [34]. The scheme for this type of compound to store and 
release NO are as follows: exposing the free amines in a compound to NO gas that will generate 
an N-diazeniumdiolate structure, 2R2NH + 2NO  R2N[N(O)NO]- + R2NH2+, in which NO is 
stored; releasing NO is achieved through allowing the N-diazeniumdiolates contacting with water 
or other protonated media to decompose the N-diazeniumdiolate, R2N[N(O)NO]
- + H+  R2NH 
+ 2NO. According to this scheme, it looks likely to functionalise MOFs with N-diazeniumdiolate 
groups to enhance NO storage and release.   
Preparation of MOFs with amine functionalities is the prerequisite condition for this type of 
NO donor. The pore size and volume in the MOFs must have to be big enough to accommodate 
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amine functionalities, which to the most extent allows NO to access amines to form N-
diazeniumdiolates. For this purpose, three approaches can be used: (a) adsorption of amine 
compounds in pores; (b) binding amine compounds to the metal centres in MOFs; (c) using organic 
ligands containing amines to build MOFs. For examples, to take advantage of N-diazeniumdiolates 
in NO delivery, it is the first to incorporate amines into MOF, such as through the pyridyl-N of 4-
(methylamino)-pyridine (4-map) to coordinate with the Cu site in HKUST-1 using vapor-phase 
diffusion method (Fig. 5 section A) [35]. Subsequently, the MOFs are exposed to NO gas (at 
pressure 2 bar) to form N-diazeniumdiolates. When exposed to moisturised air, the N-
diazeniumdiolated HKUST-1 continuously release NO for 5 days. A concern was about the N-
diazeniumdiolate group facilitated 4-map leaching in water, which may restrict the applications of 
materials in the aqueous environment. This needs to be considered when using a similar method 
for fabricating NO donors. Another method is through post- modification [36a], that is, the amine 
ligands in MOFs are converted to N-diazeniumdiolate structures. For instance, the parent MOFs 
(IRMOF-3 and UMCM-1) were built from 2-amino-1,4-benzenedicarboxylic acid and Zn. They 
contain pendant amine groups. Since the zinc is coordinatively saturated by carboxylic oxygen 
atoms from the strut ligands, there are no open metal sites within the framework. Upon exposure 
to NO gas (~100 mbar) at room temperature, the amine groups in the ligands were converted into 
N-diazeniumdiolates (Fig. 5 sections B and C). This is a crucial step to convert the parent MOFs 
into the NO donors. Distinct from the amine-functionalised HKUST-1 that is non-porous due to 
the 4-map groups converging in the pores, this material to some extent still preserves porosity. 
However, upon soaking in aqueous solution, they have the same issue of amine-leaching similar 
to the N-diazeniumdiolate functionalised HKUST-1. Peikert et al synthesised the HKUST-1 
analogous MOFs from amino functionalized trimesic acid ligands (H3RNHbtc, R=Me, Et, 
nPr, and 
iPr). This is different from the post modification, the secondary amines directly inherit from the 
ligand building blocks. To keep the structure integration, the thermal activation was controlled at 
120oC and NO loading was operated in the gas-solid reaction without a basic medium [36b].  
2.4 Polymer composites as NO donors 
In addition to nanoporous zeolites and MOFs, in recent years, development of other polymeric 
NO donors have also been investigated. These NO donors contain the moieties of S-nitrosothiols, 
nitrosamines, NO−metal complexes, organic nitrites, nitrates and the compounds containing N-
diazeniumdiolates. The common practice is to disperse thiol or amine containing compounds in 
polymers, followed by exposure to NO to convert parent materials into NO donors.  
To achieve this, three approaches are usually used through the incorporation of N-
diazeniumdiolate type NO donors into polymer composites as shown in Fig. 6: (a) blending N-
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diazeniumdiolate compounds within polymer matrices; (b) covalently binding N-diazeniumdiolate 
groups to pendant polymer chains; (c) N-diazeniumdiolate groups covalently bound directly to the 
polymer backbone [37,38]. These approaches have a distinct impact on NO storage and release 
kinetics. In a typical example, disodium 1-[2-(carboxylato)-pyrrolidin-1-yl]diazen-1-ium-1,2-
diolate (PROLI/NO) was doped in electrospun polymer microfibers, which increased the half-life 
of NO-releasing by 2 - 200 times longer than that of PROLI/NO alone [39a]. Since the NO release 
follows a water substitution mechanism, the hydrophobic or hydrophilic property of polymer 
substrates will strongly affect water permeating into polymer matrices to contact NONOate or 
RSNO segments to trigger NO-releasing. This was also elucidated by a comparison between 
poly(vinyl chloride) (PVC) and polyurethane (PU) polymers as substrates. PVC was the 
hydrophobic polymer, whereas PU was the hydrophilic polymer. The NO release half-life of the 
PVC polymer was prolonged much more than that of the PU polymer [39a]. In addition to the 
direct method using polymers or composites for delivering NO, the indirect method has been 
studied by Neufeld et al [39b]. In this case the water-stable copper-based MOF 
H3[(Cu4Cl)3(BTTri)8](H3BTTri = 1,3,5-tris(1H-1,2,3-triazol-5-yl)benzene) or Cu-BTTri was 
incorporated within the polysaccharide chitosan to form membranes. Such MOF/polymer plays a 
catalyst role in promoting the NO generation from the RSNO S-nitrosoglutathione (GSNO). They 
claimed that MOF structure was retained during exposed in aqueous solution; the formulated 
materials can be reused without significant degradation of its activity. This result supports the 
development of future MOF-based biomaterials.  
In-depth reviews covering polymer composites for the release of NO have been published 
previously [6,40], these provide a more detailed analysis of promising macromolecular materials 
and nanoparticle technology for future biomedical applications. As mentioned before, grafting the 
NO donors on different carriers will create new NO delivery materials having varied behaviours 
of NO storage and release. For example, the RS-NO and N-NONOate type NO donor groups were 
grafted on nanoparticle surfaces. Various silica particles are within the scope of the NO donor 
precursors [26, 37, 41-45], among which the N-diazeniumdiolate and thiol functionalised particles 
are of particular interests in the development of potential medical devices with various biological 
functions, e.g. inhibition of platelet aggregation, locally vasodilating blood vessels, enhancement 
of wound healing and anti-bacterial.   
2.5 Functionalised particles as NO donors 
2.5.1 N-diazeniumdiolate Functionalised particles  
The N-diazeniumdiolate functionality is a characteristic structure formed in many NO donor 
materials. In aqueous media, it spontaneously dissociates into NO and the parent amine. The 
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recovered amine present in aqueous media (such as blood) to some degree is the setback for small 
molecule N-diazeniumdiolate compounds to deliver NO because it is an undesirable by-product. 
An improvement is to disperse N-diazeniumdiolate compounds into polymers [37]. However, this 
is not an ideal solution, since some N-diazeniumdiolate compounds leaching out from the polymer 
matrix is difficult to be avoided. This raises a potential toxicity issue because it could be oxidised 
in blood into a carcinogenic N-nitrosamine. The concern of toxicity could be significantly reduced 
if parent amine compounds are covalently anchored to polymer chains or backbone, thus reducing 
the risk of labile amines leaching into the blood [26,37].  
A strategy is to graft N-diazeniumdiolates on the surface of fumed silica particles that are then 
embedded within the given polymer matrices [41]. In a special case, the amine-containing silanes 
were grafted and then converted into N-diazeniumdiolate structures after exposure to NO gas (at 
~ 5.5 bars). The advantage of this approach is to create a variety of NO-releasing polymers with 
reduced toxicity risk through embedding the N-diazeniumdiolate-functionalised, fumed silica 
particles within polymer matrices. Thereafter, the NO donor polymer can be adapted for various 
specific medical applications. For example, to devise a polymer film able to prevent the adhesion 
of platelets; topical creams for wound healing; or some products that can locally vasodilate blood 
vessels [41, 44]. 
In order to enhance the NO storage of silica particles and improve control over the NO release 
kinetics, Schoenfisch et al investigated a new class of amine-functionalized silica nanoparticle for 
NO release [43, 45-47]. The silica nanoparticles contain amine groups, created by the sol-gel 
process [48] through co-condensation of tetraethoxy- or tetramethoxysilane (TEOS or TMOS) and 
aminoalkoxysilane with an alcohol solvent and an ammonia catalyst. Subsequent exposure of the 
derived particles to NO gas (~ 5.0 bars) transforms the amine groups into N-NONOates, 
completing the conversion of silica particles into N-diazeniumdiolate NO donors (Fig. 7). The 
chemistry and amount of aminoalkoxysilane in reactants gave the final NO storage in a wide range 
of 0.05 –1.78 mmol g-1. The best result is equivalent to that of metal-exchanged zeolites. The 
maximum amount of NO released are 10 − 5500 ppb·mg-1 with half-lives 0.1 − 12 hours and 
release durations up to 30 hrs. As with the other N-diazeniumdiolate NO donors, the release is 
triggered by exposure to moisture at biologically relevant pH and temperature (pH 7.4, 37°C), 
hence its advantage for biomedical applications. This type of material favours storing large 
quantities of NO and modulating NO release kinetics over large macromolecular donors. Now, 
various silica nanoparticles have been widely studied for medical uses, if the amine or 
diazeniumdiolate leaching can be well restricted, this would be one of the promising methods. 
Analogously, this method can be used for the formulation of zeolite particles. To get rid of amine 
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leaching issue, another strategy could be adopted such as the photolysis of nitro to produce NO. 
Taladriz-Blanco et al have demonstrated a Layer-by-layer assembled gold nanoparticles that were 
achieved by alternate coating of the Au core with the cationic polyelectrolyte PAH and the tailored 
anionic polyelectrolyte PAA-NO. The NO released is regulated by the NO photoprecursor layers 
[39].  
2.5.2 Thiol-functionalised silica particles 
In a similar process as mentioned above, the thiol-functionalized silica particles have been 
fabricated from mercaptosilane and alkoxysilane [49]. After reaction with nitrous acid nitrosates, 
the thiols in the particles were converted into S-NO groups i.e. RS-H + HNO2  RS-NO + H2O. 
The formation of the red colour particles after nitrosation is an indicator of a successful reaction. 
Similar to the low molecular weight S-nitrosothiol NO donors, the derived RSNO- functionalised 
silica particle is sensitive to light. Under the light excitation at visible band ~ 550 nm, the S–N 
bond is cleaved to release NO (Fig. 8) [50]. The S-nitrosothiol silica particles mixed with polymers 
to form the polymer composites has been used as NO photo-donors for bioactive NO delivery 
[51a],  for example, Chang et al prepared NO-releasing core/shell nanoparticles possessing silica 
cores and S-nitrosothiol-modified chitosan shells [51b].  The thiol-functionalised silica particle 
overcomes the shortages observed in the low molecular weight RSNOs (such as S-nitroso-
glutathione (GSNO), S-nitroso-N-acetylcysteine (SNAC), and S-nitroso-N-acetyl-penicillamine 
(SNAP)) that have a low NO storage capacity and uncontrollable NO release [52a]. The particles 
made by the sol-gel process store more NO within the network (~4.40 mmol NO g-1) than the 
fumed silica particles that have the S-NO groups grafted on the exterior surfaces only, and they 
can release NO in a more controllable manner. For other interesting nitric oxide-releasing 
polymeric nanoparticles, dendrimers and micelles, for biomedical applications, see the recent 
review [51c].     
3. Biological tests of NO-releasing solids 
Biological tests have proved the pivotal roles of the NO released from functionalised solids in 
such roles as inhibiting platelet aggregation and anti-adhesion of platelets on surfaces and defence 
against microbial infection. The following are the typical results reported in recent publications.  
3.1 Relaxing smooth muscle of blood vessels 
As a signal messenger, NO plays a key role in vasodilatation in the body by causing smooth 
muscle of blood vessels to relax, widening blood vessels and hence easing the blood flow and 
reducing pressure. Correspondingly, the medicines used for the treatment of heart disease and 
angina are capable of producing NO in the body through enzyme conversion to affect the relaxation 
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of smooth muscle and dilate blood vessels, increasing their diameter and thereby increasing blood 
flux. An interesting experiment, using MOF NO donor demonstrated this biological function of 
NO, in which a pressed pellet MOF CPO-27 (Ni) was used [27]. Under physiological conditions, 
the MOF pellet placed a distance of 2 mm from the pig coronary arteries in an organ bath released 
NO, rapidly resulting in relaxation of the precontracted vessel. Subsequent removal of the pellet 
from the organ bath gradually recovers muscle tension.    
In a recent study of novel metal-NONOates as NO-donors, the relaxation of precontracted rat 
coronary aortas has been observed. The binding of the NONOate derived from N-
aminoethylpiperazine N-diazeniumdiolate to the metal affects the NO release rate. The nickel-
based complex [Ni(PipNONO)Cl] proved more effective than DETA/NO, a widely used and 
commercially available N-diazeniumdiolate, at inducing relaxation of the precontracted rat aortic 
rings. The effect of the Ni complex was concentration dependent. The copper analogue as 
compared demonstrated a slower release rate than the Ni complex and the unbound N-
diazeniumdiolate, however, it was ineffective at inducing vasorelaxation [53].  
In addition to the beneficial effects of NO delivered in inducing vasodilation in the cardiac 
system, there has been a recent study published demonstrating the potential of NO-delivering 
nanoparticles for the treatment of liver fibrosis and portal hypertension, using both in vitro and in 
vivo experiments [54]. Non-cytotoxic polymeric nanoparticles were designed in the studies to 
deliver NO into hepatic stellate cells (HSCs) through the S-nitrosoglutathione NO-donor 
compound. These nanoparticles targeted at HSCs in order to limit their impact on surrounding 
systems. Results demonstrated the uptake by primary rat HSCs and human HSC cell lines in the 
liver. When vitamin A coated nanoparticles reach the liver cells and release NO, inhibition of 
collagen I and α-smooth muscle actin production is observed, indicating a reduction in the 
progression of liver fibrosis. A reduction in portal pressure of around 20 % was also observed, 
which demonstrates the potential of the NO-releasing nanoparticles to alleviate portal hypertension 
as well as liver fibrosis. 
3.2 Inhibition of cancer cell growth  
At a low-level nitric oxide acts as a cellular signalling molecule and vasodilator, with other 
beneficial biological roles such as its involvement in wound healing and immune defence. 
However, when the concentration is increased NO can cause damage to mitochondria and DNA 
by nitrosation or oxidation [55]. It is such effect that has led to research into the anti-cancer 
potential of NO-releasing materials. Due to the damaging nature of high NO concentration, it is of 
particular importance to have targeted delivery of the payload.  
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The antitumor efficacy of NO delivered by silica particles against human ovarian tumour was 
evaluated by Schoenfisch et al [46]. They showed the high antitumor activity of nanoparticle-
derived NO against ovarian tumour or transformed cell lines than that of NO released from a small 
molecule NO donor, pyrrolidine (PYRRO)/NO. Silica nanoparticles deliver NO to permeate into 
the cytosol of the treated cells and remain localised to late endosomes and lysosomes. The different 
N-diazeniumdiolate-functionalized silica particles prepared from 3-methylaminopropyl-
trimethoxysilane (MAP3), N-(6-Aminohexyl) aminopropyltrimethoxysilane (AHAP3) and 3-
aminopropyltrimethoxysilane (APTMS), respectively, via sol-gel polymerization, have the 
particle size in the range of 90 - 350 nm controlled by varying aminoalkoxysilane molar percentage 
(10 - 75 mol %, balance TEOS). Particle size-dependent tumour cell cytotoxicity was observed; 
larger nanoparticles demonstrated the enhanced destabilisation of mitochondrial function and 
caspase-induced apoptosis in tumour versus non-tumor cells. This selectivity makes it possible to 
develop NO-based chemotherapies with increased antitumor efficacy and decreased toxicity to 
non-cancerous cells. For future applications, modification of the solid surface with polyethylene 
glycol (PEG) is of interests in increasing biocompatibility of this type of particles. 
N-diazeniumdiolates have shown potential as NO donors in cancer treatments due to the 
spontaneous dissociation of NO upon exposure to physiological conditions. The recent studies 
demonstrated the possibility to manipulate NO release by selecting the protecting groups that are 
able to stabilise the N-diazeniumdiolate functionalities until exposure to an enzyme when the N-
diazeniumdiolate anion was cleaved resulting in the physiological triggering of NO dissociation 
[56]. Escherichia coli nitroreductase, an enzyme not usually found in normal human cells, triggers 
the metabolism of the protected N-diazeniumdiolate (NTR), 1-(2-methylpiperidin-1-yl)diazen-1-
ium-1,2-diolate which is an inactive NO prodrug to produce the reactive N-diazeniumdiolate anion. 
Subsequently, the N-diazeniumdiolate anion releases NO upon exposure to physiological liquid at 
pH = 7.4. The NTR activated approach with the enhanced selective toxicity towards cancer cells 
illustrates potential future applications. 
In addition to the tumoricidal potential of high concentration of NO, low dose of NO has also 
demonstrated efficacy in cancer treatments by reducing anti-cancer drug resistance when used 
alongside chemotherapy [55]. Multi-drug resistance is a common problem with anti-cancer drug 
therapies, which is frequently linked to the presence of membrane proteins called P-glycoprotein 
(P-gp). These proteins draw the chemotherapy drugs out from the tumour cells, reducing the 
intracellular concentration and thereby reducing the efficacy as anti-tumor agents. The increased 
efficacy of anti-cancer drugs has been observed when they were used in conjunction with NO-
releasing drugs. The study used MCF-7 human breast cancer cell lines treated with doxorubicin 
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(DOX) chemotherapeutic drug. Upon release of NO from NO-donor modified nanoparticles, P-gp 
expression was reduced, leading to higher concentrations of DOX within the cancer cell lines and 
improved anti-tumor efficacy. This demonstrates that the NO/DOX combination is able to 
overcome multi-drug resistance [55]. 
3.3 Inhibition of platelet aggregation and adhesion 
The NO released from various classes of functionalised solids e.g. metal-exchanged zeolites 
[9, 10, 24], MOFs [24, 30, 57, 58] and silica nanoparticles [41, 44] playing an important role in 
the inhibition of platelet aggregation and adhesion has been observed [9]. Fig. 9a illustrates results 
of a platelet aggregation test using Co-exchanged zeolite LTA, in which platelet aggregation was 
initiated using the thromboxane A2 analogue, U46619 (8 íM). The cobalt exchanged zeolite 
without loaded NO (control) and LTA zeolite (blank) did not prevent platelet aggregation, only an 
NO-loaded Co-exchanged zeolite-A/PTFE (polytetrafluoroethylene) sample completely inhibits 
platelet aggregation in platelet-rich plasma (PRP). The central role of NO released from the sample 
was confirmed by the addition of the NO scavenger, oxyhaemoglobin (40 íM), which prevents the 
inhibitory effect. The NO loaded MOF (HKUST-1) also demonstrated the ability to inhibit platelet 
aggregation [24]. To examine the potential biomedical application of new NO-releasing solids, 
NO-releasing fumed silica particles were dispersed into polyurethane layer of Tygon medical 
tubing device [41]. It was found that the PU/Sil-2N[6]-N2O2Na coating on the inner wall of the 
Tygon tubing generated NO-flux levels to effectively prevent platelet aggregation and adhesion 
on inner wall of tubing (Fig. 9c), whereas the PU/silica surfaces that did not release NO had no 
inhibitory effect (Fig. 9b).  
Prevention of platelet aggregation and adhesion is of particular importance following surgical 
procedures, as the interaction of foreign materials with blood causes haemostasis disruption, which 
can lead to the formation of thrombus. Medical implants such as stents and catheters have a 
tendency to cause thrombus formation; this is problematic as it can result in failure of the implanted 
device. Research into localised delivery of NO to inhibit platelet aggregation and adhesion has 
resulted in two primary approaches: a) coating implants with novel NO-releasing materials; b) 
surface modification to incorporate NO-releasing materials. N-diazeniumdiolate and S-nitrosothiol 
NO donors have been the focus of research due to their controllable release kinetics and facile NO 
dissociation under physiological conditions, that makes them ideal NO donors for incorporation 
into modified surface materials and thin film coatings [59].  
3.4 Topical promotion of wound healing activity 
The NO-releasing zeolite (Ze-NO) that contains Mn exchanged was compared with acidified 
NO2
- when being applied for topical therapy [60]. It was found that Ze-NO had the same role as 
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acidified NO2
- in increasing dermal blood flow. However, Ze-NO did not cause any side effects 
such as marked erythema, edema, and ulceration observed in the acidified NO2
- treatment. It 
neither causes infiltration of macrophages and neutrophils into the epidermis and dermis nor 
reduces Langerhans cells in the epidermis like acidified NO2
- did. Both acidified NO2
- and NO-
releasing zeolite resulted in a moderate increase in dermal T cells. Pure NO released from Ze-NO 
can diffuse across the epidermis to the dermis to exert its biological activity and induces a moderate 
Th1-cell response. It concluded that Ze–NO is an effective NO donor without the dramatic pro-
inflammatory effects found in an ascorbic acidified NO2
-. 
In another study by Neidrauer et al [61], a topical ointment containing NO-loaded zinc-
exchanged zeolite A (33% w/w) have antimicrobial, anti-inflammatory and wound healing effects. 
NO-loaded zinc-exchanged zeolite A powder was mixed with an emulsifying ointment. The effect 
on wound closure was examined by application of ointment to the cutaneous wound on obese male 
Zucker rats, three times per week for twenty days, commencing the day after wounding. Wound 
area was calculated at various stages using image analysis and MATLAB software. For wounds 
treated with NO loaded zeolite, the average rates of healing were 15.1 % per day, compared with 
the control zeolite without NO loaded, 11.7 %. It thus demonstrates the statistically significant 
benefit of the NO loaded zeolite. Combining the NO loaded zeolite with the hydrophobic ointment 
reduces the NO release rate by at least one-third due to the reduced rate of water transport to the 
zeolite particles. Antimicrobial and anti-inflammatory effects were also observed from the NO-
loaded zeolite; these combined actions improve the efficacy of this material for topical treatment 
of wound healing. 
3.5 Antimicrobial activity 
Gaseous NO at a level ~200 ppm is effective to kill bacteria without damaging human dermal 
fibroblasts [4]. At this level, NO kills both gram-positive and gram-negative bacteria, including 
methicillin-resistant Staphylococcus aureus (MRSA). The use of nanoparticles as NO delivery 
vehicle was found to significantly enhance the efficacy of NO to kill bacteria beyond that of small 
molecule bactericidal alone. The N-diazeniumdiolate functionalised silica nanoparticles were 
capable of delivering NO [43] and killed P. aeruginosa cells more effectively than a small N-
diazeniumdiolate (i.e. PROLI/NO) [3]. The amount of NO required from PROLI/NO to completely 
kill P. aeruginosa was approximately one order of magnitude greater than that required from the 
N-diazeniumdiolate functionalized nanoparticles. Obviously, this is attributed to a low local 
concentration of NO yielded from the PROLI/NO when dispersed in both PBS and TSB solutions 
that did not diffuse into bacterial cells effectively. It is interesting to find that the NO released from 
nanoparticles at certain levels is cytotoxic only to P. aeruginosa cells but not human and mouse 
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dermal fibroblasts. More studies showed that the NO released from these particles also killed a 
series of biofilm-based microbial cells including Pseudomonas aeruginosa, Escherichia coli, 
Staphylococcus aureus, Staphylococcus epidermidis, and Candida albicans, in particular, gram-
negative P. aeruginosa and E. coli biofilms [2]. Bear in mind, these bacteria plague a high 
percentage of all leg and foot ulcers resulting in chronic wounds with impaired healing and are 
common causes of burn wound infections leading to significant morbidity and mortality in burn 
wound victims. To address unmet medical need, the development of high-efficiency NO-releasing 
nanoparticles to kill bacteria is particularly expected to enhance wound healing. In addition to 
wound healing, the N-diazeniumdiolate functionalised nanoparticles can also be formulated into 
an oral care composite with additional antimicrobial agents for oral care applications, allowing 
NO to be released from particles to diffuse through biofilms and kill oral bacteria preventing 
infection [62].   
In a recent study by Brisbois et al [63], the efficacy of an N-diazeniumdiolate NO-donor was 
assessed for antimicrobial actions in a mouse burn model. The delivery of NO was via polymer 
film doped with DBHD/N2O2 (N-diazeniumdiolate NO donor) and poly(lactic-co-glycolic) acid 
(PLGA), which promoted and prolonged NO release. The wound was exposed to Acinetobacter 
baumannii and allowed to incubate for twenty-four hours prior to application of NO-releasing 
patch, control patch or no patch. Following twenty-four hours of patch treatment, the sample was 
excised, homogenised and grown on agar plates. A significant reduction (~ 4 logs) in bacteria 
present in NO-treated samples was observed when compared to control samples, thus illustrating 
the potential antimicrobial benefits of NO-releasing materials. 
4.  In summary 
So far a diversity of NO delivery materials, e.g zeolites, MOFs and silica particles have been 
developed, which demonstrate a wide spectrum of characteristics in NO storage and releasing.  
Distinct from the endogenous NO delivery, the current material-based technologies for exogenous 
NO delivery mostly rely on the active centres present in materials e.g. the amine and thiol 
functionalities, and the uncoordinated metal sites. The pore structures of materials influence the 
accessibility of these centres to NO molecules. Undoubtedly, the concentration of these centres or 
the material porosity determines the NO storage capacity and controls the deliverable amount of 
NO. Meanwhile, the interaction between NO and the storage material determines the storage 
stability and controls the NO release profile. Consequently, the knowledge of material 
characteristics in relation to NO storage and release is necessary for the intelligent NO donor 
design. To meet the reuirements of material cytotoxicity to health cells, new NO delivery solids 
should avoid the use of toxic metals and restrict their leaching, so does the amine leaching if amines 
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are incorporated. Formulation of polymer composite containing the materials as metioned above 
will be attractive for practical use.    
Currently, many different NO delivery materials have been designed to suit different 
therapeutic applications as it is a challenge for one type of NO delivery method to meet all practical 
requirements. For example, the requirements of an NO-releasing material proposed for the 
destruction of cancer cells will be vastly different from that intended to promote wound healing 
and antimicrobial activity. The dosage of NO required for these two actions differs greatly. Exact 
doses of NO required to activate particular biological responses is unknown yet. This is an area 
where research is still required before progression into a clinical setting will be possible, but trends 
can be observed which show that much higher doses are required for cytotoxicity (nanomolar range) 
than for cellular signaling (picomolar range) to induce the regulation of blood flow and promotion 
of wound healing. Materials exhibiting a high capacity for NO loading are essential for introducing 
anti-tumor effects than for many of the other functions, however, with the provision of being able 
to introduce controllable NO release, a high capacity donor will allow for prolonged release times 
thus reducing the number of dose administrations required. For the development of optimal 
therapeutic NO delivery materials, the focus must remain on tuning the NO release rate or flux. In 
order to know targets for each application, further biological studies are required to quantitatively 
establish NO concentration ranges where the desired effects are observed. So far the information 
about the toxicology of the NO delivery materials reviewed as above is much limited. The 
corresponding investigation is required in order to clarify the material feasibility for medical uses.  
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Figures  
 
Fig. 1. (a) Structure of the cobalt-NO complex in zeolite LTA; (b) hysteric adsorption and 
desorption of nitric oxide on cobalt exchanged zeolite LTA (Modified from ref. [4] with 
ACS permission).  
 
Fig. 2.  The integrated NO release from zeolite LTA exchanged with Mn might be divided into 
two parts kinetically. One has high NO-releasing rate constant k2 that tends to release 
NO faster than the other with lower k1. This indicates the non-uniform of NO interacting 
with the framework. 
 
Fig. 3.  Structural transformation of Cu-SIP MOF and NO gating adsorption. (a) left: hydrated 
structure; right: dehydrated structure. (b) left: low-temperature diffraction spots 
observed in relation to the hydrated structure (at 300K); middle: no diffraction spots 
observed (390 K); right: high-temperature diffraction spots observed in the dehydrated 
structure (465 K). (c) Gating effect induced by structural transformation leads NO 
adsorption and desorption to a big hysteresis. Beyond a threshold (~270mbar), the 
framework was opened allowing NO to be adsorbed. (Modified from ref. [29] with ACS 
permission)    
 
Fig. 4. Activation removes the coordinated water bound to metal sites and water adsorbed in 
channels. Loading NO allows these opened metal sites to bind NO. When the material 
is exposure to a controlled humidity atmosphere such as human skin surface, the water 
substitutes NO bound to metal sites, discharges NO to meet medical needs. The material 
is H2O-solvatedly regenerated for recharging NO. (Modified from ref. [27a] with ACS 
permission).    
 
Fig. 5. Embedment of N-diazeniumdiolate (NONOate) within MOFs. Section A: 4-(methylamino)-
pyridine (4-map) was bound to the open Cu sites in the MOF HKUST-1, followed by 
exposure to NO to form the NONOates; section B and C: converting the inherited amine 
groups into the NONOates in the IRMOF-3 and UMCM-1 MOFs, respectively. 
(Modified from ref. [35] and [36a] with RSC and ACS permission).   
 
Fig. 6.  Three approaches to convert polymers into N-diazeniumdiolate type NO donors 
(Reproduced from ref. [37] with permission of Elsevier publisher). 
 
Fig. 7.  Silica nanoparticles were produced by a co-condensation reaction TEOS or TMOS and 
aminoalkoxysilane. Under the basic condition, the amine groups incorporated in 
particles were converted into N-diazeniumdiolate that decomposes to release NO in the 
PBS solution (pH=7.4, at a body temperature) (Modified from ref. [43, 45, 46] with 
ACS permission). 
 
Fig. 8.  Schematic photoinitiated NO release from the RSNO functionalised silica particles. 
 
Fig. 9. (a) Nitric oxide loaded Co- exchanged zeolite LTA completely inhibited platelet 
aggregation in platelet-rich plasma (PRP); (b) platelet aggregation and adhesion on the 
PU/silica surface (without NO released); (c) no platelet aggregation and adhesion 
occurs on the NO-releasing coating (PU/Sil-2N[6]-N2O2Na) surfaces. (Modified from 
ref. [10] and [44] with ACS and NPG permissions). 
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Fig. 1. (a) Structure of the cobalt-NO complex in zeolite LTA; (b) hysteric adsorption and 
desorption of nitric oxide on cobalt exchanged zeolite LTA (Modified from ref. [4] with 
ACS permission).  
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Fig. 2.   The integrated NO release from zeolite LTA exchanged with Mn might be divided into 
two parts kinetically. One has high NO-releasing rate constant k2 that tends to release NO faster 
than the other with lower k1. This indicates the non-uniform of NO interacting with the framework. 
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Fig. 3. Structural transformation of Cu-SIP MOF and NO gating adsorption. (a) left: hydrated 
structure; right: dehydrated structure. (b) left: low-temperature diffraction spots observed in 
relation to the hydrated structure (at 300 K); middle: no diffraction spots observed (390 K); right: 
high-temperature diffraction spots observed in the dehydrated structure (465 K). (c) Gating effect 
induced by structural transformation leads NO adsorption and desorption to a big hysteresis. 
Beyond a threshold (~270 mbar), the framework was opened allowing NO to be adsorbed. 
(Modified from ref. [29] with ACS permission)    
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Fig. 4. Activation removes the coordinated water bound to metal sites and water adsorbed in 
channels. Loading NO allows these opened metal sites to bind NO. When the material is exposure 
to a controlled humidity atmosphere such as human skin surface, the water substitutes NO bound 
to metal sites, discharges NO to meet medical needs. The material is H2O-solvatedly regenerated 
for recharging NO. (Modified from ref. [27] with ACS permission).    
 27 
 
 
 
 
Fig. 5. Embedment of N-diazeniumdiolate (NONOate) within MOFs. Section A: 4-(methylamino)-
pyridine (4-map) was bound to the open Cu sites in the MOF HKUST-1, followed by exposure to 
NO to form the NONOates; section B and C: converting the inherited amine groups into the 
NONOates in the IRMOF-3 and UMCM-1 MOFs, respectively. (Modified from ref. [35] and [36a] 
with RSC and ACS permission).   
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Fig. 6. Three approaches to convert polymers into N-diazeniumdiolate type NO donors 
(Reproduced from Ref. [37] with permission of Elsevier publisher). 
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Fig. 7.  Silica nanoparticles were produced by a co-condensation reaction TEOS or TMOS and 
aminoalkoxysilane. Under the basic condition, the amine groups incorporated in particles were 
converted into N-diazeniumdiolate that decomposes to release NO in the PBS solution (pH=7.4, 
at a body temperature) (Modified from ref. [43, 45, 46] with ACS permission). 
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Fig. 8. Schematic photoinitiated NO release from the RSNO functionalised silica particles. 
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Fig. 9.  (a) Nitric oxide loaded Co- exchanged zeolite LTA completely inhibited platelet 
aggregation in platelet-rich plasma (PRP); (b) platelet aggregation and adhesion on the PU/silica 
surface (without NO released); (c) no platelet aggregation and adhesion occurs on the NO-
releasing coating (PU/Sil-2N[6]-N2O2Na) surfaces. (Modified from ref. [10] and [44] with ACS 
and NPG permissions) 
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